Karyopharm Therapeutics Inc (KPTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $394,660
Last updated: Nov 10, 2026 at 7:59 PM ET
Karyopharm Therapeutics Inc (KPTI) Earnings: Report Dates and Results
Karyopharm Therapeutics (KPTI) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Karyopharm Therapeutics reported EPS of -$3.82, below the -$1.05 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KPTI has an expected report date of Feb 10, 2027.
KPTI Earnings Call
The latest KPTI earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, KPTI beat 20 and missed 20. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 263.81% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$3.82 | -$1.05 | N/A | -263.81% | Miss | N/A | 1 | N/A | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$2.32 | -$1.53 | -$1.68 - -$1.11 | -51.63% | Miss | N/A | 3 | 0 up, 1 down | Aug 13, 2026 | $33.43M |
| Mar 31, 2026 | -$1.24 | -$1.44 | -$1.79 - -$0.98 | +13.89% | Beat | N/A | 3 | 1 up, 0 down | May 14, 2026 | $35.07M |
| Dec 31, 2025 | -$2.23 | -$2.00 | -$2.25 - -$1.75 | -11.50% | Miss | N/A | 2 | 0 up, 0 down | Feb 12, 2026 | $34.08M |
| Sep 30, 2025 | -$3.82 | -$3.25 | -$3.32 - -$3.18 | -17.54% | Miss | N/A | 2 | 0 up, 1 down | Nov 3, 2025 | $44.04M |
| Jun 30, 2025 | -$4.07 | -$3.91 | -$4.72 - -$3.47 | -4.09% | Miss | N/A | 5 | 1 up, 2 down | Aug 11, 2025 | $37.93M |
| Mar 31, 2025 | -$2.77 | -$3.09 | -$4.39 - -$0.39 | +10.36% | Beat | N/A | 4 | 2 up, 0 down | May 12, 2025 | $30.02M |
| Dec 31, 2024 | -$3.60 | -$4.03 | -$5.25 - -$2.85 | +10.67% | Beat | N/A | 5 | 0 up, 2 down | Feb 19, 2025 | $30.54M |
| Sep 30, 2024 | -$3.90 | -$3.92 | -$5.10 - -$2.55 | +0.51% | Beat | N/A | 7 | 0 up, 0 down | Nov 5, 2024 | $38.78M |
| Jun 30, 2024 | -$4.34 | -$4.47 | -$4.95 - -$3.00 | +2.91% | Beat | N/A | 7 | 1 up, 0 down | Aug 6, 2024 | $42.79M |
| Mar 31, 2024 | -$4.80 | -$4.94 | -$5.55 - -$4.20 | +2.83% | Beat | N/A | 7 | 0 up, 0 down | May 8, 2024 | $33.13M |
| Dec 31, 2023 | -$0.36 | -$0.31 | -$0.36 - -$0.26 | -16.13% | Miss | N/A | 7 | 0 up, 1 down | Feb 29, 2024 | $33.75M |
| Sep 30, 2023 | -$4.50 | -$4.29 | -$4.80 - -$3.45 | -4.90% | Miss | N/A | 10 | 0 up, 0 down | Nov 2, 2023 | $36.01M |
| Jun 30, 2023 | -$4.35 | -$5.04 | -$5.85 - -$4.65 | +13.69% | Beat | N/A | 9 | 1 up, 1 down | Aug 2, 2023 | $37.58M |
| Mar 31, 2023 | -$4.50 | -$5.23 | -$7.95 - -$4.65 | +13.96% | Beat | N/A | 9 | 1 up, 0 down | May 4, 2023 | $38.70M |
| Dec 31, 2022 | -$6.45 | -$5.38 | -$6.30 - -$3.60 | -19.89% | Miss | -193.5% | 10 | 1 up, 0 down | Feb 15, 2023 | $33.58M |
| Sep 30, 2022 | -$6.75 | -$8.02 | -$10.94 - -$5.25 | +15.84% | Beat | N/A | 9 | 0 up, 0 down | Nov 3, 2022 | $36.15M |
| Jun 30, 2022 | -$9.30 | -$9.55 | -$12.14 - -$7.50 | +2.62% | Beat | N/A | 9 | 0 up, 0 down | Aug 4, 2022 | $39.68M |
| Mar 31, 2022 | -$7.95 | -$9.24 | -$11.54 - -$6.90 | +13.96% | Beat | N/A | 10 | 0 up, 0 down | May 5, 2022 | $47.67M |
| Dec 31, 2021 | $6.90 | -$6.37 | -$12.89 - $6.15 | +208.32% | Beat | N/A | 9 | 2 up, 0 down | Feb 8, 2022 | $126.27M |
| Sep 30, 2021 | -$10.35 | -$10.27 | -$10.94 - -$8.40 | -0.78% | Miss | N/A | 9 | N/A | Nov 3, 2021 | $37.69M |
| Jun 30, 2021 | -$10.65 | -$10.97 | -$12.74 - -$9.75 | +2.92% | Beat | N/A | 10 | N/A | Aug 5, 2021 | $22.60M |
| Mar 31, 2021 | -$11.55 | -$10.75 | -$11.69 - -$8.25 | -7.44% | Miss | N/A | 10 | N/A | May 3, 2021 | $23.26M |
| Dec 31, 2020 | -$8.85 | -$8.97 | -$11.24 - -$6.60 | +1.34% | Beat | N/A | 10 | N/A | Feb 11, 2021 | $35.10M |
| Sep 30, 2020 | -$10.95 | -$10.48 | -$12.29 - -$8.55 | -4.48% | Miss | N/A | 10 | N/A | Nov 2, 2020 | $21.33M |
| Jun 30, 2020 | -$9.45 | -$8.92 | -$11.54 - -$7.05 | -5.94% | Miss | N/A | 10 | N/A | Aug 4, 2020 | $33.51M |
| Mar 31, 2020 | -$11.70 | -$10.29 | -$11.99 - -$8.10 | -13.70% | Miss | N/A | 8 | N/A | May 5, 2020 | $18.14M |
| Dec 31, 2019 | -$11.40 | -$10.16 | -$11.84 - -$9.15 | -12.20% | Miss | N/A | 8 | N/A | Feb 13, 2020 | $18.10M |
| Sep 30, 2019 | -$10.05 | -$12.17 | -$13.19 - -$11.09 | +17.42% | Beat | N/A | 8 | N/A | Nov 4, 2019 | $13.15M |
| Jun 30, 2019 | -$10.65 | -$14.29 | -$17.24 - -$10.94 | +25.47% | Beat | N/A | 9 | N/A | Aug 6, 2019 | $9.49M |
| Mar 31, 2019 | -$16.35 | -$12.89 | -$14.69 - -$8.85 | -26.84% | Miss | N/A | 10 | N/A | May 9, 2019 | $155000 |
| Dec 31, 2018 | -$0.96 | -$0.85 | -$1.01 - -$0.53 | -12.94% | Miss | N/A | 10 | N/A | Feb 28, 2019 | N/A |
| Sep 30, 2018 | -$11.85 | -$13.15 | -$14.24 - -$11.99 | +9.89% | Beat | N/A | 10 | N/A | Nov 8, 2018 | $478000 |
| Jun 30, 2018 | -$9.00 | -$12.03 | -$14.39 - -$9.30 | +25.19% | Beat | N/A | 10 | N/A | Aug 7, 2018 | $19.89M |
| Mar 31, 2018 | -$11.70 | -$9.62 | -$12.74 - -$2.10 | -21.62% | Miss | N/A | 11 | N/A | May 10, 2018 | $10.00M |
| Dec 31, 2017 | -$0.80 | -$0.65 | -$0.69 - -$0.60 | -23.08% | Miss | N/A | 10 | N/A | Mar 15, 2018 | $1.53M |
| Sep 30, 2017 | -$9.75 | -$9.45 | -$10.94 - -$9.15 | -3.17% | Miss | N/A | 10 | N/A | Nov 2, 2017 | N/A |
| Jun 30, 2017 | -$9.60 | -$9.77 | -$12.29 - -$8.40 | +1.74% | Beat | N/A | 11 | N/A | Aug 8, 2017 | $3000 |
| Mar 31, 2017 | -$10.65 | -$9.59 | N/A | -11.05% | Miss | N/A | N/A | N/A | May 4, 2017 | $68000 |
| Dec 31, 2016 | -$0.65 | -$0.66 | N/A | +1.52% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $47000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$12.89, after -$16.64 the year before. It was -$34.85 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$12.89 | N/A |
| Dec 31, 2024 | -$16.64 | N/A |
| Dec 31, 2023 | -$13.71 | N/A |
| Dec 31, 2022 | -$30.45 | N/A |
| Dec 31, 2021 | -$25.65 | N/A |
| Dec 31, 2020 | -$40.95 | N/A |
| Dec 31, 2019 | -$48.45 | N/A |
| Dec 31, 2018 | -$33.51 | N/A |
| Dec 31, 2017 | -$30.80 | N/A |
| Dec 31, 2016 | -$34.85 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,400 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,393 | 11 | |
| 2026Q1 | Mar 31, 2026 | 6,835 | 13 | |
| 2025Q4 | Dec 31, 2025 | 7,831 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,612 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,687 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,090 | 11 | |
| 2024Q3 | Sep 30, 2024 | 6,361 | 10 |
2026Q2 Earnings Call
Opening remarks
Brendan Strong Senior Vice President, Investor Relations Good morning, and thank you all for joining us on today's conference call to discuss Karyopharm's second quarter 2026 financial results and recent company progress. We issued a press release this morning detailing our financial results for the second quarter of 2026. This release, along with the slide presentation that we will reference during our call today, are available on our website. For today's call, as shown on slide 2, I'm joined by Richard, Reshma, Sohanya, and Lori, who will review our second quarter financial results, provide an update on the significant progress we've made advancing our myelofibrosis program, discuss the clinical and regulatory momentum supporting our planned sNDA submission, and review our financial position and capital allocation priorities. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide 3. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our most recent Form 10-Q or 10-K on file with the SEC and in other filings we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any later date. I'll now turn the call over to Richard. Please turn to slide 5.
Richard Paulson Chief Executive Officer Thank you, Brendan, and good morning, everyone, and thank you for joining us today. The second quarter marked the beginning of an important new chapter for Karyopharm as we advanced selinexor from a compelling and differentiating Phase III data set toward our planned supplemental new drug application under the FDA's Accelerated Approval Pathway for patients with myelofibrosis. Over the past several months, we've remained focused, moved with urgency, and executed against an ambitious plan from generating and presenting the SENTRY data to publishing the results in the Journal of Clinical Oncology to working collaboratively with the FDA to establish a regulatory pathway as we prepare our planned submission. The SENTRY study demonstrated statistically significant, rapid, deep, and sustained spleen responses, together with preliminary overall survival findings and evidence of potential disease modification. These findings have now been presented at leading international scientific meetings, published in a peer-reviewed journal, and continue to generate strong interest globally among the hematology community.
Frequently Asked Questions About KPTI
When is Karyopharm Therapeutics's next earnings date?
Karyopharm Therapeutics's next earnings report is expected for Feb 10, 2027.
Did KPTI beat earnings estimates last quarter?
No. Karyopharm Therapeutics reported EPS of -$3.82 for the quarter ended Sep 30, 2026, below the -$1.05 estimate by 263.81%.
What EPS do analysts expect from KPTI next quarter?
The consensus EPS estimate for Karyopharm Therapeutics for the quarter ending Dec 31, 2026 is -$0.62 from 5 analysts, with estimates from -$0.83 to -$0.33.
How often does KPTI beat earnings estimates?
Karyopharm Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -39.21%.
KPTI pages: Overview, Earnings, Forecast, Financials, Competitors